Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland

[1] Gray OM(2008)Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland Mult Scler 7 880-886

[2] McDonnell GV(2004)Latitudinal variation in the prevalence of multiple sclerosis in Ireland an effect of genetic diversity J Neurol Neurosurg Psychiatry 75 572-576

[3] Hawkins SA(2007)Estimation of the cost of MS in Europe: extrapolations from a multinational cost study Mult Scler 13 1054-414

[4] McGuigan C(1987)A pilot trial of Cop 1 in exacerbating–remitting multiple sclerosis N Engl J Med 317 408-1276

[5] McCarthy A(1995)Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1268-297

[6] Quigley C(2001)European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis European/Canadian Glatiramer Acetate Study Group Ann Neurol 49 290-933

[7] Bannan L(2006)Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy N Engl J Med 354 924-77

[8] Hawkins SA(2007)Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis J Neurol 254 67-684

[9] Hutchinson M(2006)IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event Neurology 66 678-792

[10] Sobocki P(2005)Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study Arch Neurol 62 785-866

[1] Gray OM(2008)Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland Mult Scler 7 880-886

[2] McDonnell GV(2004)Latitudinal variation in the prevalence of multiple sclerosis in Ireland an effect of genetic diversity J Neurol Neurosurg Psychiatry 75 572-576

[3] Hawkins SA(2007)Estimation of the cost of MS in Europe: extrapolations from a multinational cost study Mult Scler 13 1054-414

[4] McGuigan C(1987)A pilot trial of Cop 1 in exacerbating–remitting multiple sclerosis N Engl J Med 317 408-1276

[5] McCarthy A(1995)Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1268-297

[6] Quigley C(2001)European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis European/Canadian Glatiramer Acetate Study Group Ann Neurol 49 290-933

[7] Bannan L(2006)Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy N Engl J Med 354 924-77

[8] Hawkins SA(2007)Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis J Neurol 254 67-684

[9] Hutchinson M(2006)IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event Neurology 66 678-792

[10] Sobocki P(2005)Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study Arch Neurol 62 785-866